By MEGGLE Excipients
Introducing ultra-low nitrite lactose at CPHI China in Shanghai
Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE is returning for an eleventh consecutive occasion to Asia’s leading pharma industry expo, CPHI China in Shanghai.
MEGGLE will use this year’s expo to introduce its recently introduced ultra-low nitrite range of lactose excipients to the Asian market.
Premium low nitrite grades
MEGGLE will again be found in CPHI China’s Pharma Excipients Zone at the Shanghai New International Expo Center (SNIEC), at its large stand at Booth E3E02, exhibiting in partnership with its local agents, Guangzhou-based Standard Pharma Ltd (SP). and Shanghai Pintech Pharmaceutical Co (PT).
A centerpiece of the MEGGLE display will be its premium low nitrites lactose grades, including new versions of GranuLac® 200, Tablettose® 100 and FlowLac® 100, with further grades in development. All are measured and validated as having ultra-low nitrite levels well below the limit of under one tenth of a part per million recently stipulated as ‘safe’ by the US Pharmacopoeia (USP) Nitrosamine Exchange Forum. This is to address the increasingly urgent pharma industry concern over nitrosamine impurities in pharma formulations.
Other products on show will include highly tailored specialties such as FlowLac® spray-dried lactose developed especially for direct compression (DC) processes, co-processed lactose (1+1>2), and InhaLac® for dry powder inhaler DPI applications – all meeting China Food and Drug Administration (CFDA) standards to make them particularly relevant to China’s huge pharma manufacturing industry.
Shanghai team
MEGGLE’s event team will be led by the chief representative of its Shanghai-based China Bureau, Dr. Yi Kang, who will be on stand throughout the show, along with Ruth Leinenbach, who since 2017 has headed the Excipients & Technology Business Group. On Day Two of the show (June 25), there will also be an opportunity to meet Tristan Mul, who recently took charge of DPI dry powder inhalation products.
The team will focus on meeting existing and potential customers, deepening its relationship with local partners PT and SP and sharing knowledge on industry-leading trends.
MEGGLE will also be a prominent presence on the WeChat official networking site that supports CPHI China, with a QR code for instant connection (see Images).
About MEGGLE
Bavarian-based company MEGGLE is one of the world’s experts in co-processing and powder technology. From its roots as a dairy operation in the late 1880’s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical grade lactose, supplying the pharmaceutical industry with a broad-based and unique lactose product portfolio.
MEGGLE’s Business Unit Excipients has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.
A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovation in industrial milk and whey processing. The company constantly strives to develop high-technological, functional products for solid dosage forms and DPI applications, where they can deliver maximum performance.
The company has introduced several revolutionary products, notably Tablettose®, the world’s first agglomerated pharmaceutical lactose grade for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on powdered cellulose and lactose for outstanding compression and flow properties and RetaLac®, the first direct compressible co-processed excipient using Hypromellose and lactose for sustained release formulations.
To learn more, visit: https://www.meggle-pharma.com/en/home.html
About CPHI China 2025
Over the first quarter of the 21st century, CPHI China has established itself as the leading pharma industry business and sourcing event for Eastern Asia, reflecting the huge growth of the Chinese pharma market. The event serves as a critical platform for sourcing, networking, and exploring innovations in pharmaceutical ingredients, manufacturing, and packaging.
CPHI China 2025 is a three-day event opening June 24 at the Shanghai New International Exhibition Center (SNIEC), co-located with the P-Mec machinery and equipment show. As Asia’s premier pharmaceutical trade event, it brings together over 3,500 exhibitors and more than 90,000 attendees from across the global pharma supply chain.
The expo is organized into specialized zones, including Pharma Ingredients, Finished Dosage, Natural Extracts, BioTech, Pharma Excipients, and Contract Services, providing attendees with targeted opportunities to connect with key players in specific sectors . A robust conference agenda complements the exhibition, featuring over 100 content sessions led by industry experts. Topics include pharmaceutical quality, innovation, ecological manufacturing practices, and the API market.
CPHI China is organized by Shanghai Sinoexpo Informa Markets International Exhibition Co. Ltd (IM Sinoexpo) with further information at http://www.cphi-china.cn/en
Resources
Click on MEGGLE low nitrite grades for further information.
Click on Risk Mitigation of Nitrosamines Formation in Drug Products: Role of Excipients to download MEGGLE White Paper.